Chlorpromazine induced fluid retention masquerading as idiopathic oedema An abnormality in dopaminergic tone has been implicated in the pathogenesis of idiopathic oedema. Chlorpromazine has antidopaminergic activity, and we describe a patient in whom chlorpromazine was reproducibly associated with severe fluid retention.
Case report
A 45 year old woman was investigated for severe, persistent oedema of two years' duration. She had a 25 year history of schizophrenia, and two years previously she had begun treatment with chlorpromazine hydrochloride 400 mg daily. There was no history of organic disease.
Examination showed a woman 156 cm tall and weighing 70 kg. Blood pressure was 120/80 mm Hg and pulse 80/min. Swelling ofthe face, breasts, and abdomen and pitting oedema of the ankles were evident. There was no other physical abnormality. Serum urea concentration was 3-8 mmol/l, creatinine 102 mmol/l, sodium 143 mmol/l, total protein 70 g/l, and albumin 48 g/l. Results of urine analysis and an electrocardiogram and chest radiograph were all normal. Endocrine evaluation showed a free thyroxine concentration of 16-3 pmol/l and a thyroid stimulating hormone concentration of 2 0 mU/I. Resting plasma renin activity was 1-6 ig/h/l and aldosterone concentration 4-58 nmol/l (mean control values (SD) 166 (0 99) and 2 25 (0-04),respectively). After the patient had been standing for two hours her plasma renin activity rose to 5 6 jtg/h/l and aldosterone concentration to 10-45 nmol/W (mean control values 5X81 (3 30) and 6-1 i (0 09), respectively). Prolactin concentration was raised (56 gg/1).
She was treated with spironolactone 200 mg daily but with no response. There was also no diuresis with kaluril (hydrochlorothiazide 50 mg with amiloride 5 mg) and ethacrynic acid 50 mg daily. The possibility of chlorpromazine induced alterations in dopaminergic tone was considered and she received bromocriptine 7 5 mg daily for three months. No change was noted in body weight with this regimen. Chlorpromazine was then stopped. This was followed by a weight loss of 12 kg and the swelling resolved completely for the first time in two years. Six months later chlorpromazine was reintroduced because of an exacerbation of schizophrenia. She again gained weight (15 kg), accompanied by generalised swelling and facial bloating. The oedema dramatically resolved on withdrawal of the drug.
Comment
Peripheral oedema occurs in 1-3% ofpatients taking phenothiazines and other psychotropic agents associated with prominent antidopaminergic activity.1 Dopaminergic neurones enhance renal sodium excretion by a direct effect on the renal tubule and by modulating renin and aldosterone secretion.2 Evidence exists that diminished dopaminergic tone may have a pathophysiological role in the fluid retention ofidiopathic oedema. Kuchel et al found diminished urinary dopamine secretion in patients with idiopathic oedema.2 Norbiato et al reported an exaggerated rise in aldosterone concentrations in response to the dopamine antagonist metoclopramide in patients with idiopathic oedema.3 Sowers et al reported that patients with idiopathic oedema responded to the dopamine agonist bromocriptine with a diuresis. 4 By virtue of its antidopaminergic effects chlorpromazine may lead to fluid retention in patients so predisposed. The lack of response to bromocriptine in our patient while taking chlorpromazine may be accounted for by the antagonistic antidopaminergic effect ofthe phenothiazines.5
From all this evidence it is tempting to speculate that idiopathic oedema represents a range qfvarying degrees offluid retention from overt oedema to a latent tendency for fluid retention (subclinical idiopathic oedema). Cryptic diminution of endogenous dopaminergic tone, further compromised by administration ofantidopaminergic agents, might precipitate the appearance of clinically important oedema. Other undetermined factors working in concert with decreased dopaminergic tone may also play a part.
Chlorpromazine and other psychotropic drugs with definite antidopaminergic properties should be considered among the possible causes of idiopathic oedema. 
Hepatic adenomas induced by norethisterone in patients receiving renal dialysis
The association between using oral contraceptives long term and developing hepatic adenomas is known,t2 but there has been only one report of such lesions occurring in a patient with end stage renal failure who had received oestrogens and norethisterone.3 Dysfunctional uterine bleeding may be severe in patients receiving dialysis, contributes to their anaemia, may be exacerbated by anticoagulation during haemodialysis, and is difficult to treat. Continuous high dose norethisterone (up to 30 mg/day) has been used successfully, though breakthrough bleeding often occurs if the dose is reduced. We report the development of hepatic adenomas in two patients receiving dialysis who were treated with high dose norethisterone.
Case reports CASE 1 A 33 year old woman had been treated for end stage renal failure by continuous ambulatory peritoneal dialysis forfiveyears. Intermittent intraperitoneal bleeding due to retrograde menstruation had led to the peritoneal catheter blocking on several occasions, so menstruation had been suppressed by norethisterone 10 mg twice daily, which she had taken continuously for four years.
On the day of admission she developed acute epigastric pain and abdominal distension and the dialysate became heavily bloodstained. She was clinically shocked but resuscitated with blood transfusion, and bleeding stopped after 48 hours. Ultrasonography showed a mass in the left lobe of the liver. Computed tomography confirmed this to be a tumour measuring 12'5 x 8 0 cm and replacing most of the left lobe (figure). Two other lesions, both about 1-5 cm in diameter, were seen in the right lobe. Selective angiography confirmed that the lesion in the left lobe was hypovascular consistent with extensive necrosis. Serum a fetoprotein concentration was not increased.
After laparotomy and left hepatectomy histological examination showed a typical hepatic adenoma with no evidence of carcinoma. Postoperatively she was treated by haemodialysis and then peritoneal dialysis after one month. She was subsequently well although she did not menstruate despite withdrawal of norethisterone. Computed tomography after six months showed that the two remaining lesions had disappeared. CASE 
2
A 23 year old woman had been treated by haemodialysis for two years. Heavy uterine bleeding had become debilitating, and after serious gynaecological disease had been excluded the bleeding was suppressed with norethisterone 10 mg thrice daily.
She presented three years later with fever, neutrophilia, erythrocyte sedimentation rate 155 mm inthe first hour, and abnormal results of liver function tests. Abdominal ultrasonography showed multiple intrahepatic lucencies. Computed tomography showed several masses containing areas of calcification in both hepatic lobes, the appearances suggesting a multifocal liver tumour. Histological examination of a biopsy specimen showed hepatic adenoma but no malignancy.
She died three months later from a cardiac arrhythmia. Permission for necropsy was refused.
Comment
This is the first report of hepatic adenomas developing during treatment with norethisterone alone. The women had received continuous high dose norethisterone for three and-four years respectively, and in both, unusually, the adenomas were multiple. The risk of adenomas increases with duration of contraceptive treatment and high oestrogen dosage,i2 but the effects of different doses of progestogen are not known. 2 Both women had end stage renal failure requiring dialysis, and data on progestogen metabolism in such patients are few.4 As the drug is normally excreted in the urine, however,5 high concentrations of norethisterone and its conjugate metabolites may have accumulated in our patients. These cases show the need for caution in using norethisterone in patients with renal impairment, and modification of recommended doses may be necessary.
Hepatic adenomas may remain undiagnosed until quite large1 and may present suddenly with. lifethreatening complications. Regular ultrasonography should lead to their early detection in patients at high risk.
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